C-Myb regulates matrix metalloproteinases 1/9, and cathepsin D: Implications for matrix-dependent breast cancer cell invasion and metastasis

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Knopfová, Lucia ^a,b   Beneš, Petr ^a,b   Pekarčíková, Lucie ^a   Hermanová, Markéta ^b   Masařík, Michal ^a   Pernicová, Zuzana ^b,c   Souček, Karel ^b,c   Šmarda, Jan ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

Breast cancer; C Myb; Cathepsin D; Extracellular matrix; Matrix metalloproteinase; Metastasis

Indexed keywords

CATHEPSIN D; COMPLEMENTARY DNA; GELATINASE B; INTERSTITIAL COLLAGENASE; PROTEIN C MYB; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CONTROLLED STUDY; ENZYME REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; METASTASIS; METASTASIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL MOTION; FEMALE; GENETICS; IMMUNOBLOTTING; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

MUS;

ANIMALS; BREAST NEOPLASMS; CATHEPSIN D; CELL LINE, TUMOR; CELL MOVEMENT; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; IMMUNOBLOTTING; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-MYB; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 84858722491     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-15     Document Type: Article

References (87)

1. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer 2008, 8:523-534. 10.1038/nrc2439, 18574464.
2. Roussel M, Saule S, Lagrou C, Rommens C, Beug H, Graf T, Stehelin D. Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation. Nature 1979, 281:452-455. 10.1038/281452a0, 226888.
3. Jin S, Zhao H, Yi Y, Nakata Y, Kalota A, Gewirtz AM. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J Clin Invest 2010, 120:593-606. 10.1172/JCI38030, 2810070, 20093773.
4. Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela JM, Dik WA, Langerak AW, Montpellier B, Nadel B, Walrafen P, et al. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 2007, 110:1251-1261. 10.1182/blood-2006-12-064683, 17452517.
5. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, Mentens N, Beverloo HB, Pieters R, Speleman F, et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 2007, 39:593-595. 10.1038/ng2025, 17435759.
6. Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 2009, 106:18740-18744. 10.1073/pnas.0909114106, 2773970, 19841262.
7. Ramsay RG, Thompson MA, Hayman JA, Reid G, Gonda TJ, Whitehead RH. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa. Cell Growth Differ 1992, 3:723-730.
8. Guerin M, Sheng ZM, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 1990, 5:131-135.
9. Gonda TJ, Leo P, Ramsay RG. Estrogen and MYB in breast cancer: potential for new therapies. Expert Opin Biol Ther 2008, 8:713-717. 10.1517/14712598.8.6.713, 18476782.
10. Kauraniemi P, Hedenfalk I, Persson K, Duggan DJ, Tanner M, Johannsson O, Olsson H, Trent JM, Isola J, Borg A. MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res 2000, 60:5323-5328.
11. Drabsch Y, Ramsay RG, Gonda TJ. MYB suppresses differentiation and apoptosis of human breast cancer cells. Breast Cancer Res 2010, 12:R55. 10.1186/bcr2614, 2949644, 20659323.
12. Chen L, Xu S, Zeng X, Li J, Yin W, Chen Y, Shao Z, Jin W. c-myb activates CXCL12 transcription in T47D and MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai) 2010, 42:1-7.
13. Quintana AM, Liu F, O'Rourke JP, Ness SA. Identification and Regulation of c-Myb Target Genes in MCF-7 Cells. BMC Cancer 2011, 11:30. 10.1186/1471-2407-11-30, 3038977, 21261996.
14. Liu F, Lei W, O'Rourke JP, Ness SA. Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb. Oncogene 2006, 25:795-805. 10.1038/sj.onc.1209105, 16205643.
15. Tanno B, Sesti F, Cesi V, Bossi G, Ferrari-Amorotti G, Bussolari R, Tirindelli D, Calabretta B, Raschella G. Expression of slug is regulated by C-MYB and is required for invasion and bone marrow homing of cancer cells of different origin. J Biol Chem 2010, 285:29434-29445. 10.1074/jbc.M109.089045, 2937976, 20622260.
16. Chen RX, Xia YH, Xue TC, Ye SL. Transcription factor c-Myb promotes the invasion of hepatocellular carcinoma cells via increasing osteopontin expression. J Exp Clin Cancer Res 2010, 29:172. 10.1186/1756-9966-29-172, 3023683, 21190594.
17. Thorner AR, Parker JS, Hoadley KA, Perou CM. Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. PLoS One 2010, 5:e13073. 10.1371/journal.pone.0013073, 2951337, 20949095.
18. Ungefroren H, Groth S, Sebens S, Lehnert H, Gieseler F, Fandrich F. Differential roles of Smad2 and Smad3 in the regulation of TGF-beta1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: control by Rac1. Mol Cancer 2011, 10:67. 10.1186/1476-4598-10-67, 3112431, 21624123.
19. Petrella BL, Brinckerhoff CE. Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase. Mol Cancer 2006, 5:66. 10.1186/1476-4598-5-66, 1764426, 17140440.
20. Sodek KL, Ringuette MJ, Brown TJ. MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. Br J Cancer 2007, 97:358-367. 10.1038/sj.bjc.6603863, 2360333, 17609667.
21. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000, 291:113-135. 10.1016/S0009-8981(99)00224-7, 10675719.
22. Sodek KL, Brown TJ, Ringuette MJ. Collagen I but not Matrigel matrices provide an MMP-dependent barrier to ovarian cancer cell penetration. BMC Cancer 2008, 8:223. 10.1186/1471-2407-8-223, 2519089, 18681958.
23. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000, 6:4823-4830.
24. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000, 2:252-257. 10.1186/bcr65, 138784, 11250717.
25. Benes P, Vetvicka V, Fusek M. Cathepsin D-many functions of one aspartic protease. Crit Rev Oncol Hematol 2008, 68:12-28. 10.1016/j.critrevonc.2008.02.008, 2635020, 18396408.
26. Scott PG, Pearson H. Cathepsin D: specificity of peptide-bond cleavage in type-I collagen and effects on type-III collagen and procollagen. Eur J Biochem 1981, 114:59-62.
27. Handley CJ, Mok MT, Ilic MZ, Adcocks C, Buttle DJ, Robinson HC. Cathepsin D cleaves aggrecan at unique sites within the interglobular domain and chondroitin sulfate attachment regions that are also cleaved when cartilage is maintained at acid pH. Matrix Biol 2001, 20:543-553. 10.1016/S0945-053X(01)00168-8, 11731271.
28. Cesi V, Casciati A, Sesti F, Tanno B, Calabretta B, Raschella G. TGFbeta-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER + breast cancer cells. Cell Cycle 2011, 10:4149-4161. 10.4161/cc.10.23.18346, 22101269.
29. Schultz J, Lorenz P, Ibrahim SM, Kundt G, Gross G, Kunz M. The functional -443 T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol Carcinog 2009, 48:14-23. 10.1002/mc.20452, 18459127.
30. Strohmaier AR, Spring H, Spiess E. Three-dimensional analysis of the substrate-dependent invasive behavior of a human lung tumor cell line with a confocal laser scanning microscope. Histochem Cell Biol 1996, 105:179-185. 10.1007/BF01462290, 8681035.
31. Ehlers EM, Bakhshandeh A, Wiedemann G, Kuhnel W. Invasiveness of human pleural mesothelioma cells is influenced in vitro by the three-dimensional structure of the ECM and its composition. Ann Anat 2002, 184:417-424. 10.1016/S0940-9602(02)80072-3, 12392321.
32. Saito K, Shimizu F, Sato T, Oite T. Modulation of human mesangial cell behaviour by extracellular matrix components-the possible role of interstitial type III collagen. Clin Exp Immunol 1993, 91:510-515. 1554724, 8443971.
33. Tatti O, Arjama M, Ranki A, Weiss SJ, Keski-Oja J, Lehti K. Membrane-type-3 matrix metalloproteinase (MT3-MMP) functions as a matrix composition-dependent effector of melanoma cell invasion. PLoS One 2011, 6:e28325. 10.1371/journal.pone.0028325, 3229567, 22164270.
34. Bhattarai G, Lee YH, Lee NH, Yun JS, Hwang PH, Yi HK. c-myb mediates inflammatory reaction against oxidative stress in human breast cancer cell line, MCF-7. Cell Biochem Funct 2011, 29:686-693. 10.1002/cbf.1808, 21953443.
35. Khalkhali-Ellis Z, Hendrix MJ. Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation. Cancer Res 2007, 67:3535-3539. 10.1158/0008-5472.CAN-06-4767, 3177104, 17440060.
36. Rushton JJ, Davis LM, Lei W, Mo X, Leutz A, Ness SA. Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins. Oncogene 2003, 22:308-313. 10.1038/sj.onc.1206131, 12527900.
37. Rochefort H. Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer 1992, 28A:1780-1783.
38. Garcia M, Derocq D, Pujol P, Rochefort H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 1990, 5:1809-1814.
39. Masson O, Bach AS, Derocq D, Prebois C, Laurent-Matha V, Pattingre S, Liaudet-Coopman E. Pathophysiological functions of cathepsin D: Targeting its catalytic activity versus its protein binding activity?. Biochimie 2010, 92:1635-1643. 10.1016/j.biochi.2010.05.009, 20493920.
40. Abbott DE, Margaryan NV, Jeruss JS, Khan S, Kaklamani V, Winchester DJ, Hansen N, Rademaker A, Khalkhali-Ellis Z, Hendrix MJ. Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology. Cancer Biol Ther 2010, 9:23-30. 10.4161/cbt.9.1.10378, 3187721, 19923884.
41. Johnson MD, Torri JA, Lippman ME, Dickson RB. The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 1993, 53:873-877.
42. Glondu M, Liaudet-Coopman E, Derocq D, Platet N, Rochefort H, Garcia M. Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene 2002, 21:5127-5134. 10.1038/sj.onc.1205657, 12140763.
43. Tedone T, Correale M, Barbarossa G, Casavola V, Paradiso A, Reshkin SJ. Release of the aspartyl protease cathepsin D is associated with and facilitates human breast cancer cell invasion. FASEB J 1997, 11:785-792.
44. Ohri SS, Vashishta A, Proctor M, Fusek M, Vetvicka V. Depletion of procathepsin D gene expression by RNA interference: a potential therapeutic target for breast cancer. Cancer Biol Ther 2007, 6:1081-1087. 10.4161/cbt.6.7.4325, 17611405.
45. Ohri SS, Vashishta A, Proctor M, Fusek M, Vetvicka V. The propeptide of cathepsin D increases proliferation, invasion and metastasis of breast cancer cells. Int J Oncol 2008, 32:491-498.
46. Laurent-Matha V, Maruani-Herrmann S, Prebois C, Beaujouin M, Glondu M, Noel A, Alvarez-Gonzalez ML, Blacher S, Coopman P, Baghdiguian S, et al. Catalytically inactive human cathepsin D triggers fibroblast invasive growth. J Cell Biol 2005, 168:489-499. 10.1083/jcb.200403078, 2171724,2171724, 15668295.
47. Beaujouin M, Prebois C, Derocq D, Laurent-Matha V, Masson O, Pattingre S, Coopman P, Bettache N, Grossfield J, Hollingsworth RE, et al. Pro-cathepsin D interacts with the extracellular domain of the beta chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth. J Cell Sci 2010, 123:3336-3346. 10.1242/jcs.070938, 2964349, 20826454.
48. Li Y, Wood N, Grimsley P, Yellowlees D, Donnelly PK. In vitro invasiveness of human breast cancer cells is promoted by low density lipoprotein receptor-related protein. Invasion Metastasis 1998, 18:240-251. 10.1159/000024517, 10729769.
49. Song H, Li Y, Lee J, Schwartz AL, Bu G. Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. Cancer Res 2009, 69:879-886. 10.1158/0008-5472.CAN-08-3379, 2633434, 19176371.
50. Dedieu S, Langlois B, Devy J, Sid B, Henriet P, Sartelet H, Bellon G, Emonard H, Martiny L. LRP-1 silencing prevents malignant cell invasion despite increased pericellular proteolytic activities. Mol Cell Biol 2008, 28:2980-2995. 10.1128/MCB.02238-07, 2293087, 18316405.
51. Tanno B, Negroni A, Vitali R, Pirozzoli MC, Cesi V, Mancini C, Calabretta B, Raschella G. Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms. J Biol Chem 2002, 277:23172-23180. 10.1074/jbc.M200141200, 11973331.
52. Bein K, Ware JA, Simons M. Myb-dependent regulation of thrombospondin 2 expression. Role of mRNA stability. J Biol Chem 1998, 273:21423-21429. 10.1074/jbc.273.33.21423, 9694906.
53. Smith CL, Hager GL. Transcriptional regulation of mammalian genes in vivo. A tale of two templates. J Biol Chem 1997, 272:27493-27496. 10.1074/jbc.272.44.27493, 9346875.
54. Ko ER, Ko D, Chen C, Lipsick JS. A conserved acidic patch in the Myb domain is required for activation of an endogenous target gene and for chromatin binding. Mol Cancer 2008, 7:77. 10.1186/1476-4598-7-77, 2572630, 18840288.
55. Wilczek C, Chayka O, Plachetka A, Klempnauer KH. Myb-induced chromatin remodeling at a dual enhancer/promoter element involves non-coding rna transcription and is disrupted by oncogenic mutations of v-myb. J Biol Chem 2009, 284:35314-35324. 10.1074/jbc.M109.066175, 2790961, 19841477.
56. Tao K, Fang M, Alroy J, Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 2008, 8:228. 10.1186/1471-2407-8-228, 2529338, 18691423.
57. Fu SL, Ganter B, Lipsick JS. Myb proteins inhibit fibroblast transformation by v-Rel. Mol Cancer 2006, 5:54. 10.1186/1476-4598-5-54, 1635057, 17081304.
58. Drabsch Y, Hugo H, Zhang R, Dowhan DH, Miao YR, Gewirtz AM, Barry SC, Ramsay RG, Gonda TJ. Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells. Proc Natl Acad Sci USA 2007, 104:13762-13767. 10.1073/pnas.0700104104, 1959456, 17690249.
59. Miao RY, Drabsch Y, Cross RS, Cheasley D, Carpinteri S, Pereira L, Malaterre J, Gonda TJ, Anderson RL, Ramsay RG. MYB is essential for mammary tumorigenesis. Cancer Res 2011, 71:7029-7037. 10.1158/0008-5472.CAN-11-1015, 21948968.
60. Nicolau M, Levine AJ, Carlsson G. Topology based data analysis identifies a subgroup of breast cancers with a unique mutational profile and excellent survival. Proc Natl Acad Sci USA 2011, 108:7265-7270. 10.1073/pnas.1102826108, 3084136, 21482760.
61. Deisenroth C, Thorner AR, Enomoto T, Perou CM, Zhang Y. Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53. Mol Cell Biol 2010, 30:3981-3993. 10.1128/MCB.01284-09, 2916441, 20547751.
62. Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J, Leffall LD. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 2005, 11:481-483. 10.1038/nm1243, 15864312.
63. Wyatt CA, Geoghegan JC, Brinckerhoff CE. Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Res 2005, 65:11101-11108. 10.1158/0008-5472.CAN-05-2446, 16322260.
64. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120:303-313. 10.1016/j.cell.2004.12.018, 15707890.
65. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I, Bar-Shavit R. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998, 4:909-914. 10.1038/nm0898-909, 9701242.
66. Yang E, Boire A, Agarwal A, Nguyen N, O'Callaghan K, Tu P, Kuliopulos A, Covic L. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 2009, 69:6223-6231. 10.1158/0008-5472.CAN-09-0187, 2733168, 19622769.
67. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K, Massague J. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007, 446:765-770. 10.1038/nature05760, 17429393.
68. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524. 10.1038/nature03799, 1283098, 16049480.
69. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang Y, Ishwaran H, et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 2007, 104:6740-6745. 10.1073/pnas.0701138104, 1871856, 17420468.
70. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massague J. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326. 10.1016/j.cell.2009.11.025, 2810531, 20064377.
71. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massague J. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133:66-77. 10.1016/j.cell.2008.01.046, 2390892, 18394990.
72. Paku S, Dome B, Toth R, Timar J. Organ-specificity of the extravasation process: an ultrastructural study. Clin Exp Metastasis 2000, 18:481-492. 10.1023/A:1011858925376, 11592305.
73. Pugsley MK, Tabrizchi R. The vascular system. An overview of structure and function. J Pharmacol Toxicol Methods 2000, 44:333-340. 10.1016/S1056-8719(00)00125-8, 11325577.
74. Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone?. Cancer Metastasis Rev 2008, 27:41-55. 10.1007/s10555-007-9109-4, 18071636.
75. Arnold S, Mira E, Muneer S, Korpanty G, Beck AW, Holloway SE, Manes S, Brekken RA. Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Exp Biol Med (Maywood) 2008, 233:860-873.
76. de Vries JE, Dinjens WN, De Bruyne GK, Verspaget HW, van der Linden EP, de Bruine AP, Mareel MM, Bosman FT, ten Kate J. In vivo and in vitro invasion in relation to phenotypic characteristics of human colorectal carcinoma cells. Br J Cancer 1995, 71:271-277. 10.1038/bjc.1995.55, 2033572, 7841040.
77. Ungefroren H, Sebens S, Seidl D, Lehnert H, Hass R. Interaction of tumor cells with the microenvironment. Cell Commun Signal 2011, 9:18. 10.1186/1478-811X-9-18, 3180438, 21914164.
78. Mareel MM, Van Roy FM, De Baetselier P. The invasive phenotypes. Cancer Metastasis Rev 1990, 9:45-62. 10.1007/BF00047588, 2208568.
79. Bies J, Nazarov V, Wolff L. Identification of protein instability determinants in the carboxy-terminal region of c-Myb removed as a result of retroviral integration in murine monocytic leukemias. J Virol 1999, 73:2038-2044. 104446, 9971784.
80. Takahashi T, Suwabe N, Dai P, Yamamoto M, Ishii S, Nakano T. Inhibitory interaction of c-Myb and GATA-1 via transcriptional co-activator CBP. Oncogene 2000, 19:134-140. 10.1038/sj.onc.1203228, 10644988.
81. Smarda J, Zemanova K, Bryja J, Smardova J, Kozubik A, Hofmanova J, Nemajerova A, Sevcikova S, Kohoutek J, Vodicka P. Retinoid X receptor suppresses transformation by the v-myb oncogene. J Leukoc Biol 1999, 66:1039-1048.
82. Wang F, Duan R, Chirgwin J, Safe SH. Transcriptional activation of cathepsin D gene expression by growth factors. J Mol Endocrinol 2000, 24:193-202. 10.1677/jme.0.0240193, 10750020.
83. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998, 58:5321-5325.
84. Benanti JA, Williams DK, Robinson KL, Ozer HL, Galloway DA. Induction of extracellular matrix-remodeling genes by the senescence-associated protein APA-1. Mol Cell Biol 2002, 22:7385-7397. 10.1128/MCB.22.21.7385-7397.2002, 135658, 12370286.
85. Benes P, Maceckova V, Zdrahal Z, Konecna H, Zahradnickova E, Muzik J, Smarda J. Role of vimentin in regulation of monocyte/macrophage differentiation. Differentiation 2006, 74:265-276. 10.1111/j.1432-0436.2006.00077.x, 16831196.
86. Smarda J, Sugarman J, Glass C, Lipsick J. Retinoic acid receptor alpha suppresses transformation by v-myb. Mol Cell Biol 1995, 15:2474-2481. 230477, 7739532.
87. Welch DR. Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis 1997, 15:272-306. 10.1023/A:1018477516367, 9174129.